ABSI

7.5107.97%
ZJ

Zachariah Jonasson

Chief Business Officer & CFO

Dr. Zachariah Jonasson, Ph.D., served as Co-Founder & Managing Partner at Phoenix Venture Partners since April 2018 and also served as its Managing General Partner till April 2018. He was lead their investment strategy in life sciences and healthcare. He serves as Co-Founder & Senior Advisor at Convergent Ventures LLC. Before Convergent Ventures, Zach was a General Partner and led seed fund investments in Valence, ProFluent, and Totient. He was a Co-Founder and Director of Comera Life Sciences Holdings, Inc. Dr. Jonasson is a Co-Founder and Director at Crop Enhancement LLC and served as its Vice President of Business Development. He served as a Director of Green Theme Technologies, Inc. He is a Co-Founder & Chief Executive Officer of ReForm Biologics. Dr. Jonasson is a Co-Founder of NanIO with Dr. Soane. He has experience in research and development, business development operating roles, start-up investments and start-up executive and turn-around roles in several start-ups such as Valeritas and Nephrion. He has experience in venture capital, entrepreneurship and start-ups operations. He was a General Partner, Senior Principal and Kauffman Fellow at Seaflower Ventures, Inc. He built a successful track record sourcing and leading investments in advanced materials start-ups focused on life science applications. At Seaflower, Dr. Jonasson works closely with Nephros Therapeutics in various operating roles. Dr. Jonasson has several years of research experience in Biotechnology and Finance and several years of experience working with technology start-ups. Dr. Jonasson was a Member of the five person team that built Risk Capital Management Partners (RCM) and served as a Consultant at the firm, where he consulted with various early-stage technology companies. At RCM, he developed instruments and led engagements with major chemicals and energy producers, such as Eastman Chemical, Shell Chemical and Sempra. Dr. Jonasson serves on the Commercialization Council for Oregon Nanoscience and Microtechnologies Institute. Additionally, he serves as Board Member at eMed Technologies. He served as Director of Absci Corporation since April 2016 until 2024 and serves as its Chief Business Officer and CFO since August 31, 2023. He serves as a Board Member of Traycer Systems, Inc. and BroadSpot Imaging Corporation. He serves on the Advisory Board for the Oregon Innovation Cluster (OIC) and is actively involved with the Kauffman Fellows Program. He served as the Chairman of Absci Corporation. Dr. Jonasson also co-taught Market Research at Harvard Business School and Harvard College and co-authored two studies of applied real options and risk analysis with Professor David Shimko. As a Sackler Scholar, Dr. Jonasson was awarded several research grants, led a research collaboration and authored several scientific articles. Dr. Jonasson previously served as a director on the boards of L7 Informatics, Inc., Micropore, Inc., Xandar Kardian, Inc. He previously served on the board of the Oregon Translational Research and Development Institute (OTRADI) and Oregon Bioscience Incubator (OBI). He holds a MD in Statistics and Ph.D. in Neuroscience as a Sackler Scholar in the Cognition, Brain and Behavior program at Harvard University in 2002 and a B.S. from the SFS Honors Program at Georgetown University in 1994, where he was a Rhodes Scholarship Finalist.

Positions